<DOC>
	<DOCNO>NCT03062007</DOCNO>
	<brief_summary>This study evaluate safety tolerability BI-CON-02 patient HER2-positive metastatic breast cancer , previously treat trastuzumab The clinical trial protocol BI-CON-02 prescribes start dose 0,3 mg/kg . After Data Safety Monitoring Committee evaluate data tolerability safety BI-CON-02 , receive 3 week investigational product therapy ( Week 3 , Day 1 ) approves , extra dos use . Once safety investigational product confirm , dose increase subsequent cohort . Planned dose - 0,3 mg/kg ; 0,6 mg/kg ; 1,2 mg/kg ; 2,4 mg/kg ; 3,6 mg/kg 4,8 mg/kg .</brief_summary>
	<brief_title>Open-label Study Safety , Tolerability Pharmacokinetics Multiple Doses BI-CON-02 Patients With HER2-positive Metastatic Breast Cancer , Previously Treated With Trastuzumab</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>To participate clinical study , patient must comply follow criterion : 1 . Signed patient 's information sheet informed consent form participate study 2 . Females age ≥ 18 year 3 . Histologically confirm diagnosis locally advance metastatic breast cancer . 4 . HER2positive tumor status result immunohistochemistry ( IHC3+ ) hybridization insitu ( ISH ) , receive local laboratory , experienced/certified determine HER2 expression mean accurate validate method . 5 . Disease progression trastuzumabbased chemotherapy . 6 . Previous chemotherapy metastatic breast cancer . 7 . Requirements laboratory parameter determine : Hematology : Absolute neutrophil count : Platelets : Hemoglobin : ≥ 1500/mm3 ( 1.5 x 109 cells/L ) 100 000/mm3 ( 100 x 109 cells/L ) 9.0 g/dl Liver function : Total bilirubin : Aspartate aminotransferase ( AST ) , Alanine aminotransferase ( ALT ) , Alkalinephosphatase ≤ 1.5 x ULN ≤ 2.5 x ULN ≤ 5.0 х ULN case liver and/or bone metastasis Renal function : Serum creatinine GFR ( accord CocroftGolt formula ) : ≤ 1.5 mg/dl &gt; 60 ml/min 8 . Patients must ECOG status 0 , 1 2 9 . Women childbearing potential ( sterile menopause le 2 year ) must practice effective method birth control whole period study 6 month last administration investigational product . Effective method birth control include usage condom diaphragm ( barrier method ) spermicide . The patient consider ineligible study case criterion list : 1 . Clinically significant cardiovascular disease : Myocardial infarction within 6 month screen Unstable angina within 3 month screen Congestive heart failure Class III IV accord New York Heart Association ( NYHA ) criteria Clinically significant ventricular arrhythmia , treat , include ventricular tachycardia , ventricular fibrillation , history cardiac arrest QTc interval &gt; 460 m ( ECG ) ( calculate accord Fredericia formula ) , diagnosis long QTc syndrome Ejection fraction leave ventricle ≤ 50 % ( EchoCG ) Hypotension ( systolic arterial blood pressure &lt; 86 mm mercury ) bradycardia heart rate &lt; 50 beat per min. , except cause medication ( e.g . betablockers ) Uncontrolled arterial hypertension ( systolic arterial blood pressure &gt; 170 mm mercury diastolic arterial blood pressure &gt; 105 mm mercury ) Troponins I ≥ 0.2 ng/ml 2 . Patients known cerebral metastasis clinical sign cerebral metastasis . 3 . Patients severe dyspnea rest , need additional oxygen therapy everyday life . 4 . History hypersensitivity trastuzumab ≥ 3 severity level 5 . History toxicity relate trastuzumab administration result termination trastuzumab therapy . 6 . Peripheral neuropathy ≥ II severity level 7 . Bisphosphonate therapy symptomatic hypercalcemia . 8 . Any chemotherapy , hormonotherapy , radiotherapy , immunotherapy biological product therapy use breast cancer treatment within 4 week first administration investigational product . 9 . Previous indication doxorubicin maximum cumulate dose &gt; 360 mg/kg2 , equivalent . 10 . Participation clinical study administration investigational product within 4 week first administration investigational product , presence ongoing toxicity ≥ II grade accord CTCAE , related prior antitumour therapy ( exclude alopecia ) . 11 . History malignancy exception cervical carcinoma situ skin basalcell carcinoma , undergone surgical removal treatment within ≥ 5 year first administration investigational product . 12 . Presence antibody human immunodeficiency virus ( HIV ) , hepatitis С virus ( HCV ) , presence HBsAg 13 . Active infection within 4 week first administration investigational product . 14 . Uncontrolled concomitant disease condition , include mental social , , Investigator 's opinion , may prevent patient participation study . 15 . Drug alcohol abuse moment screen past , , Investigator 's opinion , make patient unsuitable participation study . 16 . Pregnant lactate woman , woman plan get pregnant clinical study 17 . Inability read write , unwillingness understand comply procedure study protocol , well concomitant medical serious mental condition , make patient unsuitable participation clinical study , limit validity inform consent receipt may affect patient 's ability participate study .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>